Jennifer Michaelson - Sep 27, 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Development Officer, Biologics
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Sep 27, 2022
Transactions value $
-$32,400
Form type
4
Date filed
9/29/2022, 04:05 PM
Previous filing
Aug 9, 2022
Next filing
Nov 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Options Exercise $17.2K +4K +7.54% $4.30 57K Sep 27, 2022 Direct
transaction CGEM Common Stock Sale -$49.6K -4K -7.01% $12.40 53K Sep 27, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -4K -1.92% $0.00 205K Sep 27, 2022 Common Stock 4K $4.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.30 to $12.56. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Chief Development Officer, Biologics